Impact of Additional Chromosomal Aberrations Present at Diagnosis on Outcome of Adolescent and Young Adult Chronic Myeloid Leukemia Patients: A Single Center Experience

Studying the influence of additional chromosomal aberrations (ACAs) present at diagnosis on the outcome of adolescent and young adult (AYA) chronic myeloid leukemia (CML) patients as it has not been addressed previously. Eighty-six AYA CML patients have been analyzed for occurrence of ACAs at diagnosis through performing bone marrow karyotyping. All patients received imatinib mesylate upon diagnosis of CML. Overall response, molecular response, survival status, progression and occurrence of events were monitored during the follow up period. There was a statistically significant difference between patients with and without ACAs regarding overall response ( P = 0.049). There was insignificant difference between the two groups regarding achievement of major molecular response (MMR) ( P = 0.594), MR 4 ( P = 0.282) and MR 4.5 ( P = 0.704). There was a significant difference between patients with and without ACAs regarding time to MMR ( P = 0.042) and time to MR 4 ( P = 0.048) but not regarding time to MR 4.5 ( P = 0.065). There was insignificant impact of ACAs at diagnosis on overall survival ( P = 0.152), progression free survival ( P = 0.112), failure free survival ( P = 0.114), event free survival ( P = 0.194) and alternative treatment free survival ( P = 0.731). The presence of ACAs at diagnosis does not signal worse prognosis in AYA CML patients but it may delay molecular response to imatinib mesylate.